Neutralizing monoclonal antibodies for COVID-19 treatment and prevention

Jaworski, Juan Pablo

doi:10.1016/j.bj.2020.11.011

Cited by 41 publications

(42 citation statements)

References 108 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from these studies indicate that tests using N and S were considered equally sensitive 14,15 . Based on these observations, it has been assumed that determination of antibody responses against either protein would be equally suitable in post-infection phase population-based seroprevalence studies 16 . However anti-S and anti-RBD antibodies correlate better with virus neutralization 17-20 .…”

Section: Introductionmentioning

confidence: 99%

An“In-House”ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes

Grau

Ploper

Ávila

et al. 2021

Preprint

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) first reported in Wuhan has caused a global pandemic with dramatic health and socioeconomic consequences. The Coronavirus Disease 2019 (COVID-19) associated represents a challenge for health systems that had to quickly respond developing new diagnostic and therapeutic strategies. In the present work, we developed an In House ELISA with high sensitivity (92.2 %), specificity (100%) and precision (93.9%), with an area under the ROC curve (AUC) of 0.991, rendering the assay as an excellent serological test to correctly discriminate between SARS-COv-2 infected and non-infected individuals and study population seroprevalence. Among 758 patients evaluated for SARS-CoV-2 diagnosis in the province of Tucuman, Argentina, we found a Pearson correlation coefficient of 0.5048 between antibodies elicited against the RBD and the nucleocapsid (N) antigen. Additionally, 33.6% of individuals diagnosed with COVID-19 displayed mild levels of RBD-IgG antibodies, while 19% of the patients showed high antibody titers. Interestingly, patients with SARS-COV-2 infection over 60 years old elicited significantly higher levels of IgG antibodies against RBD compared to younger ones, while no difference was found between women and men. Surprisingly, individuals from a high altitude village displayed statistically significant higher and longer lasting anti-RBD antibodies compared to those from a city at a lower altitude, suggesting that a hypobaric hypoxia-adapted mechanism may act as a protective factor for COVID-19. To our knowledge, this is the first report correlating altitude with increased humoral immune response against SARS-Cov-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

An“In-House”ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes

Grau

Ploper

Ávila

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…As such, there is to respite for the research to decipher the disease mechanism, monitor its evolution, and hunt for efficient therapies. This issue of the Biomedical Journal fully focuses on the most essential facets of fighting this global threat, comprising detection methods [ 2 ], vaccine design [ 3 ], drug development [ [4] , [5] , [6] , [7] , [8] ], and model systems.…”

Section: Level Up For Culture Models - How 3d Cell Culture Models Benmentioning

confidence: 99%

“…Here, Juan Jaworski provides us with an exhaustive account on the state of the art regarding the development of nMAbs against SARS-CoV-2, with a detailed description of their molecular targets and level of (pre)clinical trial [ 4 ]. Advantages and promising results are debated just as much as possible adverse events and the main hurdle consisting of high manufacturing costs.…”

Section: Also In This Issuementioning

confidence: 99%

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research

Häfner¹

2021

Biomedical Journal

View full text Add to dashboard Cite

Welcome to a new decade and a new issue of the Biomedical Journal - casting a sorrowful look onto a year that will go down in history as a tombstone etched by the COVID-19 pandemic, but also a hopeful glance into the future, now that multiple vaccination programs against the SARS-CoV-2 virus have started. This issue is dedicated to the continuous effort by researchers all around the globe to understand and counter the pathogen, as well as to be better prepared for future threats. Therefore, we learn about the advantages of complex 3D cell culture models for studying host-virus interactions, and the disease course of COVID-19 in children. Moreover, we discover how neutralising monoclonal antibodies and peptide-based vaccines against SARS-CoV-2 are developed, and the therapeutic potentials of lopinavir/ritonavir, mesenchymal stem cells, as well as plant and algae extracts. Finally, we ponder over the lessons to be learnt from SARS-CoV and MERS, and hear about differences between different nucleotide-based SARS-CoV-2 detection methods.

show abstract

“…Interleukin-6 receptor antagonists may be beneficial in patients with cytokine release syndrome, although the effectiveness is not yet clear [ 15 , 16 , 17 , 18 ]. Cocktails of potent monoclonal antibodies targeting viral spike protein are effective for the treatment and prophylaxis of COVID-19, but their use is limited by the high costs of antibody production [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Tonk

Růžek

Vilcinskas

2021

Viruses

View full text Add to dashboard Cite

Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeline for the discovery and development of antiviral drugs. One promising solution is the extensive library of antimicrobial peptides (AMPs) produced by all eukaryotic organisms. AMPs are widely known for their activity against bacteria, but many possess additional antifungal, antiparasitic, insecticidal, anticancer, or antiviral activities. AMPs could therefore be suitable as leads for the development of new peptide-based antiviral drugs. Sixty therapeutic peptides had been approved by the end of 2018, with at least another 150 in preclinical or clinical development. Peptides undergoing clinical trials include analogs, mimetics, and natural AMPs. The advantages of AMPs include novel mechanisms of action that hinder the evolution of resistance, low molecular weight, low toxicity toward human cells but high specificity and efficacy, the latter enhanced by the optimization of AMP sequences. In this opinion article, we summarize the evidence supporting the efficacy of antiviral AMPs and discuss their potential to treat emerging viral diseases including COVID-19.

show abstract

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention

Cited by 41 publications

References 108 publications

An“In-House”ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes

An“In-House”ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Contact Info

Product

Resources

About